234080 — JW Life Science Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩183bn
- KR₩197bn
- KR₩207bn
- 82
- 81
- 66
- 92
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 9,861 | 2,592 | 5,078 | 28,873 | 28,374 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 34,088 | 36,578 | 37,198 | 53,772 | 55,731 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 59,856 | 56,496 | 64,430 | 105,008 | 107,834 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 131,690 | 135,423 | 137,145 | 131,555 | 124,577 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 201,404 | 218,041 | 219,467 | 252,942 | 255,836 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 66,871 | 69,268 | 83,902 | 80,044 | 94,259 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 78,788 | 85,980 | 87,975 | 112,610 | 96,443 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Total Equity | 122,615 | 132,061 | 131,492 | 140,332 | 159,393 |
Total Liabilities & Shareholders' Equity | 201,404 | 218,041 | 219,467 | 252,942 | 255,836 |
Total Common Shares Outstanding |